CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
BACKGROUND
The patients with mild cognitive impairment (MCI) have an elevated risk for Alzheimer's disease (AD). Especially the amnestic MCI is seen as prodrome of AD. Apolipoprotein E (APOE) epsilon4 allele, abnormal CSF Abeta42, Tau and phosphorylated Tau (phospho-Tau) levels are associated with elevated risk for AD.


METHODS
APOE genotyping was done by PCR based method and baseline CSF Abeta42, Tau and phospho-Tau were measured by ELISA from 60 controls and 79 MCI patients.


RESULTS
Thirty-three MCI patients developed dementia during an average of 3.5 years follow-up. CSF Abeta42 was decreased and Tau and phospho-Tau were increased in the progressive MCI patients. The APOE epsilon4 allele was more frequent in the progressive MCI patients. The APOE epsilon4 allele showed a dose dependent association o the Abeta42 levels in the progressive MCI patients and to all of the markers in controls.


CONCLUSIONS
Decreased CSF Abeta42 and elevated Tau or phospho-Tau together with APOE epsilon4 allele are highly predictive for the dementia in MCI patients with amnestic or executive symptoms.
Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland. sanna-kaisa.herukka@uku.fi <sanna-kaisa.herukka@uku.fi>
Sanna-Kaisa
SK
Herukka
Seppo
S
Helisalmi
Merja
M
Hallikainen
Susanna
S
Tervo
Hilkka
H
Soininen
Tuula
T
Pirttilä
D000368:Aged; D000483:Alleles; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D000704:Analysis of Variance; D053327:Apolipoprotein E4 / Q000235:genetics*; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000235:genetics* / Q000401:mortality; D003704:Dementia / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D010446:Peptide Fragments; D010766:Phosphorylation; D011237:Predictive Value of Tests; D016019:Survival Analysis; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D053327:Apolipoprotein E4; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins